Ophthalmology

Glaucoma

Glaucoma study guide for medical students: definition, epidemiology, pathophysiology, clinical features, diagnosis, management, and key exam pearls.

intraocular pressureoptic nerveangle-closure

Glaucoma – Comprehensive Study Guide for Medical Students

Definition

Glaucoma is a heterogeneous group of progressive optic neuropathies characterized by loss of retinal ganglion cells and their axons, resulting in characteristic optic nerve head (optic disc) cupping and corresponding visual field defects. Elevated intraocular pressure (IOP) is a major, but not mandatory, risk factor; vision loss is typically irreversible and asymptomatic until late stages.[1](https://pubmed.ncbi.nlm.nih.gov/41837485/)

Epidemiology

Glaucoma is one of the leading causes of irreversible blindness worldwide, with prevalence increasing with age, particularly after 40 years.[2](https://pubmed.ncbi.nlm.nih.gov/41809163/)

  • Prevalence: Primary open-angle glaucoma (POAG) is the most common form globally; primary angle-closure glaucoma (PACG) is more frequent in certain Asian populations.
  • Age: Risk rises substantially after age 40; age is an independent risk factor for disease onset and progression.[2](https://europepmc.org/article/MED/41809163)
  • Sex: Angle-closure glaucoma is more common in females due to anatomic factors (shorter axial length, shallower anterior chamber).
  • Ethnicity: Higher POAG risk and more aggressive course in people of African descent; PACG more common in East and Southeast Asian populations.
  • Family history: First-degree relatives have significantly increased risk, reflecting genetic susceptibility.

Pathophysiology

The core event in glaucoma is progressive retinal ganglion cell (RGC) loss and optic nerve damage. Multiple mechanisms interact:

  • Elevated intraocular pressure (IOP): Imbalance between aqueous humor production (ciliary body) and outflow (trabecular meshwork and uveoscleral pathways) leads to increased IOP, mechanical stress at the lamina cribrosa, and axonal injury.
  • Outflow resistance in POAG: Microscopic changes in the trabecular meshwork and Schlemm canal increase outflow resistance, gradually raising IOP.
  • Angle closure in PACG: Pupillary block, plateau iris, or lens-related mechanisms narrow the anterior chamber angle, acutely or chronically obstructing trabecular outflow.
  • Vascular and perfusion factors: Impaired autoregulation and reduced optic nerve head perfusion contribute, particularly in normal-tension glaucoma (NTG).[8](https://europepmc.org/article/MED/41739125)
  • Mitochondrial dysfunction and oxidative stress: Emerging evidence implicates mitochondrial damage, disturbed bioenergetics, and oxidative stress in RGC apoptosis and glaucomatous neurodegeneration.[1](https://pubmed.ncbi.nlm.nih.gov/41837485/)
  • Neurodegeneration: Excitotoxicity, glial activation, and disordered axoplasmic flow at the lamina cribrosa contribute to progressive optic neuropathy.

Classification

Glaucoma can be classified by mechanism, anatomy, and timing:

  • By anterior chamber angle:
    • Open-angle glaucoma: Angle appears open on gonioscopy, but resistance to outflow is increased (e.g., POAG, NTG).
    • Angle-closure glaucoma: Appositional or synechial closure of the angle impedes aqueous outflow (primary or secondary).
  • By primary vs secondary:
    • Primary: No identifiable ocular/systemic cause (POAG, PACG, NTG).
    • Secondary: Due to another ocular or systemic process (uveitic, neovascular, steroid-induced, lens-induced, trauma-related, or post-surgical such as Soemmering's ring–related angle closure).[3](https://pubmed.ncbi.nlm.nih.gov/41804434/)[7](https://europepmc.org/article/MED/34662038)
  • By onset:
    • Congenital/infantile
    • Juvenile
    • Adult

Clinical Presentation

Primary Open-Angle Glaucoma (POAG)

POAG is typically insidious and asymptomatic until late.

  • Symptoms:
    • Often asymptomatic in early stages.
    • Gradual, painless, bilateral peripheral visual field loss (“tunnel vision” in advanced disease).
    • No redness or acute pain.
  • Signs:
    • Elevated IOP (although may be normal in NTG).
    • Characteristic optic disc cupping (increased cup-to-disc ratio, thinning of neuroretinal rim, especially inferior and superior).
    • Retinal nerve fiber layer (RNFL) defects on OCT.
    • Corresponding arcuate, nasal step, or paracentral scotomas on visual field testing.

Primary Angle-Closure Glaucoma (PACG)

PACG can present as an acute ophthalmic emergency or as chronic angle closure.

  • Acute angle-closure attack:
    • Severe ocular pain and headache.
    • Blurred vision, halos around lights.
    • Nausea and vomiting.
    • Red eye with ciliary flush, corneal edema (hazy cornea).
    • Mid-dilated, poorly reactive pupil.
    • Very high IOP (often > 40 mmHg).
  • Chronic angle closure:
    • More insidious, overlapping features with POAG but with narrow angles on gonioscopy and peripheral anterior synechiae.

Secondary Glaucomas

  • Lens-induced glaucoma: Occurs in association with hypermature cataract or lens material leakage/swelling, causing angle compromise or inflammatory outflow obstruction.[7](https://europepmc.org/article/MED/34662038)
  • Post-surgical angle closure (e.g., Soemmering's ring): Circumferential retained lens material can displace intraocular structures anteriorly and secondarily close the angle in pseudophakic eyes.[3](https://pubmed.ncbi.nlm.nih.gov/41804434/)
  • Uveitic, neovascular, steroid-induced, traumatic, and others: Each has characteristic associated signs (e.g., synechiae, rubeosis iridis, steroid exposure).

Diagnosis

Diagnosis requires integration of structural and functional assessments rather than reliance on IOP alone.

Key Diagnostic Components

  • History:
    • Age, family history of glaucoma or blindness.
    • Ethnicity, steroid use, trauma, ocular surgery, systemic diseases.
    • Symptoms of acute angle closure or chronic visual field loss.
  • Intraocular pressure measurement:
    • Goldmann applanation tonometry is the standard.
    • Measure at different times if diurnal variation suspected.
    • Note that NTG can occur with IOP in the statistically normal range.[8](https://europepmc.org/article/MED/41739125)
  • Gonioscopy:
    • Mandatory to classify open vs angle-closure mechanism.
    • Evaluates angle width, pigmentation, peripheral anterior synechiae, and neovascularization.
  • Optic disc evaluation:
    • Assess cup-to-disc ratio, rim thinning, notching, disc hemorrhages.
    • Look for vertical elongation of the cup and focal defects.
  • Optical coherence tomography (OCT):
    • Quantifies RNFL thickness and ganglion cell complex parameters.
    • Shows structural loss that may precede visual field change.
  • Visual field testing (standard automated perimetry):
    • Identifies characteristic patterns (arcuate scotoma, nasal step, paracentral defects).
    • Monitors progression over time.
  • Anterior segment imaging:
    • Ultrasound biomicroscopy (UBM) or anterior segment OCT to evaluate angle anatomy, plateau iris, lens position, or lesions such as Soemmering's ring in pseudophakic angle closure.[3](https://pubmed.ncbi.nlm.nih.gov/41804434/)

Diagnostic Criteria (General Principles)

  • Structural: Characteristic glaucomatous optic neuropathy on disc exam and/or RNFL loss on OCT.
  • Functional: Corresponding reproducible visual field defects on perimetry.
  • Supportive: Elevated IOP, angle findings on gonioscopy consistent with open or closed angle, and relevant risk factors.
  • Normal-tension glaucoma: Same structural and functional criteria, but with IOP within normal range, after excluding other optic neuropathies and accounting for corneal thickness and measurement artifacts.[8](https://europepmc.org/article/MED/41739125)

Management

The fundamental therapeutic goal in glaucoma management is to lower IOP to a target level that halts or markedly slows optic nerve damage and visual field loss. Target IOP is individualized based on baseline IOP, extent of damage, rate of progression, and risk factors.[8](https://europepmc.org/article/MED/41739125)

General Principles

  • Earlier and more advanced disease generally require lower target IOP.
  • Regular follow-up with IOP measurement, optic nerve/RNFL imaging, and visual fields is critical.
  • Address modifiable risk factors (e.g., glucocorticoid exposure, lifestyle factors) where relevant.[2](https://europepmc.org/article/MED/41809163)

Medical (Pharmacologic) Therapy

First-line treatment for most POAG and many NTG patients is topical ocular hypotensive medication.

  • Prostaglandin analogs (e.g., latanoprost, bimatoprost, travoprost):
    • Mechanism: Increase uveoscleral outflow.
    • Once-daily dosing, high efficacy, often first-line.
    • Adverse effects: Conjunctival hyperemia, eyelash growth, periocular skin darkening, iris pigmentation.
  • Beta-blockers (e.g., timolol, betaxolol):
    • Mechanism: Decrease aqueous humor production.
    • Contraindications: Asthma, severe COPD, bradycardia, heart block.
  • Alpha-2 agonists (e.g., brimonidine):
    • Mechanism: Decrease aqueous production and increase uveoscleral outflow.
    • Adverse effects: Allergy, fatigue, dry mouth.
  • Topical carbonic anhydrase inhibitors (e.g., dorzolamide, brinzolamide):
    • Mechanism: Decrease aqueous production.
    • Systemic formulations (acetazolamide) used in acute settings or advanced disease.
  • Rho kinase inhibitors (where available):
    • Mechanism: Improve trabecular outflow via cytoskeletal modulation.
  • Combination drops: Improve adherence by combining two mechanisms into one bottle.

Laser Therapy

  • Laser trabeculoplasty (e.g., SLT/ALT):
    • Used in open-angle glaucoma to increase trabecular outflow.
    • Can be first-line or adjunct to medical therapy.
  • Laser peripheral iridotomy (LPI):
    • Creates alternative pathway for aqueous flow between posterior and anterior chambers.
    • Mainstay in management of primary angle-closure and as prophylaxis in eyes with occludable angles.

Surgical Management

  • Trabeculectomy:
    • Creates a guarded fistula for aqueous drainage into a subconjunctival bleb.
    • Used when medical/laser therapy insufficient or not tolerated.
  • Glaucoma drainage devices (tube shunts):
    • Implant devices that divert aqueous humor to an end-plate reservoir.
    • Useful in refractory or high-risk eyes.
  • Minimally invasive glaucoma surgery (MIGS):
    • Trabecular micro-bypass stents, ab interno trabeculotomy, and other devices offering modest IOP reduction with favorable safety profiles.
    • Often combined with cataract surgery in mild–moderate disease.

Cyclodestructive Procedures

  • Ultrasound cycloplasty (UCP):
    • Uses high-intensity focused ultrasound to selectively ablate the ciliary body, reducing aqueous production.[4](https://pubmed.ncbi.nlm.nih.gov/41783060/)
    • Non-incisional, minimally invasive option for refractory glaucoma and may influence ocular biomechanics and refractive parameters.[4](https://pubmed.ncbi.nlm.nih.gov/41783060/)
  • Other cyclodestructive methods:
    • Cyclophotocoagulation (transscleral or endoscopic) for advanced or painful eyes with poor visual potential.

Management of Specific Clinical Scenarios

Primary Open-Angle Glaucoma / Normal-Tension Glaucoma

  • Initial approach:
    • Start topical monotherapy, typically a prostaglandin analog.
    • Set individualized target IOP; in NTG, aim for meaningful percentage reduction from baseline (often ≥25–30%).[8](https://europepmc.org/article/MED/41739125)
  • Escalation:
    • Add second/third agents, consider SLT, or proceed to MIGS/trabeculectomy if target IOP not achieved.
    • Assess adherence and tolerability at each visit.

Primary Angle-Closure and Angle-Closure Crisis

  • Acute angle-closure attack:
    • Rapid IOP lowering via topical and systemic agents (e.g., beta-blocker, alpha-agonist, carbonic anhydrase inhibitor, hyperosmotic agents).
    • Once cornea clears and IOP is reduced, perform definitive LPI in the affected and fellow eye.
  • Chronic angle closure:
    • LPI plus medical therapy; consider lens extraction, goniosynechialysis, or filtering surgery depending on angle anatomy and control.

Secondary Glaucoma

  • Lens-induced glaucoma:
    • IOP control with medical therapy plus definitive management of the lens pathology (e.g., cataract extraction, removal of lens material).[7](https://europepmc.org/article/MED/34662038)
  • Post-surgical angle closure (e.g., Soemmering's ring):
    • Use UBM or anterior segment OCT to confirm the cause and degree of angle compromise.[3](https://pubmed.ncbi.nlm.nih.gov/41804434/)
    • Management may require surgical removal of the ring, IOL repositioning, or glaucoma surgery.
  • Other secondary forms:
    • Treat underlying cause (inflammation, neovascularization, steroid exposure, trauma) in addition to IOP-lowering strategies.

Lifestyle and Non-Pharmacological Considerations

While IOP reduction remains the cornerstone, lifestyle and behavioral measures may have supportive roles.

  • Exercise: Regular moderate physical activity is generally associated with modest IOP reduction and improved vascular health, though care is needed in specific subgroups.[2](https://pubmed.ncbi.nlm.nih.gov/41809163/)
  • Avoidance of extreme positions: Prolonged inverted postures or head-down yoga positions can transiently raise IOP.
  • Caffeine and fluid intake: High acute fluid loads and high doses of caffeine may transiently increase IOP in some patients.
  • Smoking and systemic vascular risk factors: Optimizing systemic vascular health may be particularly relevant in NTG and in those with nocturnal hypotension.[2](https://europepmc.org/article/MED/41809163)
  • Adherence strategies: Education, simplifying regimens, and using combination drops enhance adherence and long-term outcomes.

Emerging Directions

  • Neuroprotection and mitochondria-focused therapies:
    • Increasing research into mitochondrial biology, oxidative stress, and neuroprotective strategies beyond IOP lowering, reflecting glaucoma’s neurodegenerative nature.[1](https://pubmed.ncbi.nlm.nih.gov/41837485/)
  • AI and imaging:
    • Deep learning and transformer-based models are being developed for automated detection of glaucoma from fundus photographs and OCT, potentially enabling earlier identification and risk stratification.[9](https://europepmc.org/article/MED/41619064)
    • AI is also being explored for optimizing endpoint selection in neuroprotection trials and monitoring progression.[6](https://europepmc.org/article/MED/41806927)
  • Real-world management data:
    • Observational cohorts highlight varied treatment patterns and underscore the importance of individualized target IOP and progression monitoring, especially in NTG.[8](https://europepmc.org/article/MED/41739125)

Key Clinical Pearls for Medical Students

  • 1. Glaucoma is about optic nerve damage, not just high IOP.
    • Normal IOP does not exclude glaucoma; always interpret IOP alongside optic disc, OCT, and visual fields.
  • 2. POAG is silent until late – screening in at-risk groups is crucial.
    • Patients often present late; understand risk factors (age, family history, ethnicity, thin corneas).
  • 3. Acute angle-closure glaucoma is an ophthalmic emergency.
    • Classic triad: painful red eye, decreased vision with halos, and systemic symptoms (nausea/vomiting) with markedly elevated IOP.
    • Requires rapid IOP lowering and definitive LPI once the cornea clears.
  • 4. Always perform or obtain gonioscopy in any suspected glaucoma case.
    • Differentiates open-angle from angle-closure mechanisms, which have different management pathways.
  • 5. Optic disc photography and OCT are essential for baseline and follow-up.
    • Progression (structural or functional) is more important than single measurements.
  • 6. IOP target is individualized and may need adjustment.
    • If progression occurs at target IOP, lower the target further and escalate therapy.
  • 7. Adherence is often the limiting factor in medical therapy.
    • Ask specifically about drop use, side effects, and cost barriers; simplify regimens where possible.
  • 8. Lifestyle modifications support but do not replace IOP-lowering therapy.
    • Discuss exercise, systemic vascular health, and night-time hypotension especially in NTG.[2](https://europepmc.org/article/MED/41809163)
  • 9. Think broadly about secondary causes.
    • Look for clues: uveitis, neovascularization, history of trauma, hypermature cataract, or prior surgery (e.g., Soemmering's ring, IOL malposition).[3](https://pubmed.ncbi.nlm.nih.gov/41804434/)[7](https://europepmc.org/article/MED/34662038)
  • 10. Glaucoma is chronic and lifelong.
    • Frame it for patients as a long-term condition requiring continued monitoring even if asymptomatic, with the goal of preserving functional vision throughout life.

Summary

Glaucoma is a chronic, progressive optic neuropathy and a leading cause of irreversible blindness. Diagnosis hinges on recognizing characteristic optic nerve and visual field changes, with IOP as a modifiable risk factor rather than the sole defining feature. Management focuses on individualized IOP lowering, with medical, laser, and surgical options tailored to disease type, severity, and patient characteristics. Understanding risk factors, angle anatomy, secondary causes, and the importance of longitudinal monitoring is essential for effective care and for success on exams and in clinical practice.[1](https://pubmed.ncbi.nlm.nih.gov/41837485/)[2](https://europepmc.org/article/MED/41809163)[8](https://europepmc.org/article/MED/41739125)

Have questions about Glaucoma?

Get instant, evidence-based answers from 86M+ citations.

Ask Sina about Glaucoma →

Related Topics in Ophthalmology

Diabetic Retinopathy

proliferative

Explore Other Topics

Cardiovascular

Hypertension

Cardiovascular

Heart Failure

Cardiovascular

Atrial Fibrillation

Cardiovascular

Myocardial Infarction